The genetic sequencing technology developer has filed to raise up to $100m, having secured nearly $150m from investors including Legend Capital in the past two years.
US-based genetic sequencing tool developer Singular Genomics has filed for a $100m initial public offering that would enable Legend Capital, the venture firm formed by conglomerate Legend Holdings, to exit.
Singular Genomics is working on generation sequencing technology for use in clinical research, and the two key products in its pipeline are a genetic sequencer and related suite of consumable kits known as the G4 Integrated Solution, and a cell analytics kit dubbed the PX Integrated Solution.
The IPO…
